Details of the Drug

General Information of Drug (ID: DMG3O2Z)

Drug Name
Girentuximab I-124
Synonyms Redectane (TN)
Indication
Disease Entry ICD 11 Status REF
Renal cell carcinoma 2C90 Phase 2 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
DrugBank ID
DB15025
TTD ID
D0BH7Z

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carbonic anhydrase IX (CA-IX) TT2LVK8 CAH9_HUMAN Enhancer [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Renal cell carcinoma
ICD Disease Classification 2C90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carbonic anhydrase IX (CA-IX) DTT CA9 6.08E-15 2.8 7.25
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00717587) Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer. U.S. National Institutes of Health.
2 Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.